Skip to content

Study · Case report or series · n = 1 · 2010

7 results

Exenatide-induced acute pancreatitis.

Ayoub WA, Kumar AA, Naguib HS, Taylor HC

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Jan 2010Cited by 42 (Europe PMC)

PMID19703814 (opens in a new tab)DOI10.4158/ep09104.crr (opens in a new tab)PepBankPUB-19703814
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A woman with diabetes developed epigastric pain two days after starting exenatide, with pain lasting one month.

    In plain wordsA woman with diabetes developed upper abdominal pain two days after starting exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableEpigastric pain
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide.
  2. 02HumanCase report or seriesSafety outcome

    In a woman with probable exenatide-associated pancreatitis, serum lipase exceeded the reference range.

    In plain wordsIn a woman with probable exenatide-associated pancreatitis, blood lipase exceeded the reference range.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSerum lipase
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Serum lipase
    2700 U/L
    presentation

    Source sentences

    Summary
    Serum lipase concentration was 2700 U/L (reference range, 114-320 U/L), and serum amylase concentration was 131 U/L (reference range, 30-110 U/L).
    1 context sentence
    Summary · context
    A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide.
  3. 03HumanCase report or seriesSafety outcome

    In a woman with probable exenatide-associated pancreatitis, serum amylase exceeded the reference range.

    In plain wordsIn a woman with probable exenatide-associated pancreatitis, blood amylase exceeded the reference range.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSerum amylase
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Serum amylase
    131 U/L
    presentation

    Source sentences

    Summary
    Serum lipase concentration was 2700 U/L (reference range, 114-320 U/L), and serum amylase concentration was 131 U/L (reference range, 30-110 U/L).
    1 context sentence
    Summary · context
    A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide.
  4. 04HumanCase report or seriesSafety outcome

    In a woman receiving exenatide, abdominal CT showed changes consistent with pancreatitis.

    In plain wordsIn a woman receiving exenatide, a scan showed changes consistent with pancreatitis.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicablePancreatitis on CT
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Abdominal computed tomography (CT) showed changes consistent with pancreatitis, and the gallbladder was absent.
    1 context sentence
    Summary · context
    A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 05HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome

    After exenatide withdrawal, conservative therapy rapidly resolved symptoms in the woman with pancreatitis.

    In plain wordsAfter exenatide withdrawal, conservative treatment rapidly resolved the woman's symptoms.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSymptom resolution after withdrawal
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal

    Source sentences

    Summary
    Conservative therapy resulted in rapid resolution of symptoms, normal lipase concentration (151 U/L), and normal findings from CT of the pancreas 90 days later.
    2 context sentences
    Summary · context
    Exenatide was discontinued.
    Summary · context
    A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 06HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome

    After exenatide withdrawal and conservative therapy, the woman's serum lipase normalized.

    In plain wordsAfter exenatide withdrawal and conservative treatment, the woman's blood lipase returned to normal.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLipase normalization after withdrawal
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal

    Measurements

    Serum lipase
    151 U/L
    after conservative therapy

    Source sentences

    Summary
    Conservative therapy resulted in rapid resolution of symptoms, normal lipase concentration (151 U/L), and normal findings from CT of the pancreas 90 days later.
    2 context sentences
    Summary · context
    Exenatide was discontinued.
    Summary · context
    A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 07HumanNot a test of Exenatide (exendin-4) aloneCase report or seriesSafety outcome

    After exenatide withdrawal and conservative therapy, pancreatic CT findings were normal 90 days later.

    In plain wordsAfter exenatide withdrawal and conservative treatment, the woman's pancreatic scan was normal 90 days later.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableNormal pancreatic CT after withdrawal
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal

    Source sentences

    Summary
    Conservative therapy resulted in rapid resolution of symptoms, normal lipase concentration (151 U/L), and normal findings from CT of the pancreas 90 days later.
    2 context sentences
    Summary · context
    Exenatide was discontinued.
    Summary · context
    A 64-year-old, nonalcoholic woman with NIDDM presented with a 1-month history of epigastric pain beginning 2 days after starting exenatide.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.